Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
SAN DIEGO, Feb. 03, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 p.m. ET in New York City.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner, Stern Investor Relations, Inc. 212.362.1200, [email protected]
